Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths

Similar documents
S2 File. Clinical Classifications Software (CCS). The CCS is a

TABLE C-1 RESIDENT DEATHS, LIVE BIRTHS, FETAL, INFANT, NEONATAL, AND MATERNAL DEATHS: PENNSYLVANIA,

APPENDIX ONE: ICD CODES

County of Orange Health Care Agency. Orange County Mortality Data, 2002

Orange County Mortality Data, 1999

Epidemiology in Texas 2006 Annual Report. Cancer

ANNUAL CANCER REGISTRY REPORT-2005

Cancer in Estonia 2014

Hu J, Gonsahn MD, Nerenz DR. Socioeconomic status and readmissions: evidence from an urban teaching hospital. Health Aff (Millwood). 2014;33(5).

155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary

County of Orange Health Care Agency. Orange County Mortality Data 2000

*

APPENDIX A. Comparability Ratios for the Major Causes of Death in North Carolina Vital Statistics, Volume 2

American Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013

Leading Causes of Death, Tarrant County, 2009

Suicides increased in 2014

Leading Causes of Death, Tarrant County, 2008

Leading Causes of Death, Tarrant County, 2007

0301 Anemia Others. Endocrine nutritional and metabolic disorders Others Vascular dementia and unspecified dementia

Neoplasms/Lymphoma/Leukemia

PHO: Metadata for Mortality from Avoidable Causes

Outcomes Report: Accountability Measures and Quality Improvements

Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence

National level ICD 9-3 digit Nuts II european shortlist Croatia 1999/2000 From WHO ICD-10, 4 digit. 1999/2000 From WHO ICD-10, 4 digit

Cancer Association of South Africa (CANSA)

Nov FromAtoZCodesMatter

Cancer Statistics, 2009 Ahmedin Jemal, Rebecca Siegel, Elizabeth Ward, Yongping Hao, Jiaquan Xu and Michael J. Thun. DOI: /caac.

2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill

Selected tables standardised to Segi population

Cancer in Ontario. 1 in 2. Ontarians will develop cancer in their lifetime. 1 in 4. Ontarians will die from cancer

Supplementary Online Content

A Closer Look at Leading Causes of Death in Guilford County

SUPPLEMENTARY MATERIAL

Catalogue no. 84F0209X. Mortality, Summary List of Causes

WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:

Annual Report. Cape Cod Hospital and Falmouth Hospital Regional Cancer Network Expert physicians. Quality hospitals. Superior care.

WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:

THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA

Peel Health Facts. Population Projections 2004, Region of Peel and Municipalities

From A to Z-Codes Matter

Catalogue no. 84F0209X. Mortality, Summary List of Causes

Estimated Minnesota Cancer Prevalence, January 1, MCSS Epidemiology Report 04:2. April 2004

Cancer Statistics, 2010 Ahmedin Jemal, Rebecca Siegel, Jiaquan Xu and Elizabeth Ward. DOI: /caac.20073

Cancer Statistics, 2007 Ahmedin Jemal, Rebecca Siegel, Elizabeth Ward, Taylor Murray, Jiaquan Xu and Michael J. Thun

Table A: Leading Causes of Death* by Age Group North Carolina Residents, 2016

Cancer in New Mexico 2017

Diagnosis-specific morbidity - European shortlist

Cancer in New Mexico 2014

All Discovered Death Outcome Detail (Form 124/120)

Bioengineering and World Health. Lecture Twelve

Attending Physician s Statement

Outcomes Report: Accountability Measures and Quality Improvements

Florida Cancer Data System STAT File Documentation Version 2019

Prioritized ShortList MORBIDITY

Crosswalk File of ICD9 Diagnosis Codes to Risk Group Assignment 1-Apr-15

Cancer Statistics, 2015

Cancer Statistics, 2014

Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers

Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers

Cancer A Superficial Introduction

Republican Research and Practical Center for Radiation Medicine and Human Ecology. Ilya Veyalkin Head of Laboratory of Epidemiology Gomel, Belarus

The comparability ratio is an adjustment factor

SKCC Protocol Review Committee New Study Application

Subject Cancers in Firefighters and Fire Investigators

Chapter 1: Certain Infectious and parasitic diseases (A00-B99)

Information Services Division NHS National Services Scotland

Cancer in Central and South America BOLIVIA

Cancer Statistics, 2016

Cancer in Northeastern Pennsylvania: Incidence and Mortality of Common Cancers

CANCER FACTS & FIGURES For African Americans

2016 Cancer Registry Annual Report

SUPPLEMENTARY MATERIAL Risk of cancer in patients with thyroid disease and venous thromboembolism

Key Words. Cancer statistics Incidence Lifetime risk Multiple primaries Survival SEER

Information Services Division NHS National Services Scotland

Cancer Incidence in New Jersey Implementation of the Year 2000 Population Standard

US ARMY Public Health Command

Population Population Projections 2005, Region of Peel and Municipalities Mississauga Brampton Caledon Peel Male Female

Malignancy ; 191.6; Malignant neoplasm of brain

Cancer survival in Seoul, Republic of Korea,

CODING PRIMARY SITE. Nadya Dimitrova

Premium Specialty: Pediatrics

Leading causes of death among Minneapolis residents,

Information Services Division NHS National Services Scotland

Heart Failure Transitions of Care SJMH - Ann Arbor

National Cancer Statistics in Korea, 2014

MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site

Subject Cancers in Firefighters and Fire Investigators

5.2 Main causes of death Brighton & Hove JSNA 2013

Wisconsin Longitudinal Study Codebook. Information about the Graduate Spouse s current marriage was collected in the following manner:

Impact and implications of Cancer Death Status Reporting Delay on Population- Based Relative Survival Analysis with Presumed-Alive Assumption

Samuel M. Lesko, MD, MPH Director of Research/Medical Director

Supplementary Online Content

CLIC Sargent Eligibility Criteria

Construction of a North American Cancer Survival Index to Measure Progress of Cancer Control Efforts

CHRONIC DISEASE San Luis Obispo County 59 photo credit: Barbara J. Schanz

Detection: Rabab Gaafar,MD. Prof. Medical Oncology NCI,Cairo, Cairo University

Burden of Cancer in California

Cancer in Utah: An Overview of Cancer Incidence and Mortality from

Evaluation of Ancestry Information Markers (AIMs) from Previous ACOSOG/CALGB/NCCTG Trials

Epidemiology and Impact of A Little Bit of Afib" Margot E. Vloka, MD, FACC, FHRS St. Alphonsus Regional Medical Center Heart Institute Boise, Idaho

Transcription:

RSNA, 2016 10.1148/radiol.2016152472 Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths Observed/Expected No. of Deaths Observed/Expected All causes of death 4468 0.47 8339 0.52 All malignant neoplasms (140 208, 238.6)/(C00-C97) 1398 0.52 2457 0.54 Lip, oral cavity, pharynx (140 149)/(C00-C14) 30 0.54 41 0.45 Digestive organs (150 159)/(C15-C26) 393 0.61 696 0.64 Esophagus (150/C15) 37 0.43 54 0.39 Stomach (151/C16) 41 0.56 66 0.53 Colon excluding rectum (153)/(C18) 144 0.66 243 0.65 Rectum and rectosigmoid junction (154)/(C19-C21) 20 0.44 35 0.46 Liver and intrahepatic bile duct (155)/(C22) 38 0.56 65 0.59 Pancreas (157/C25) 102 0.76 204 0.9 Respiratory and intrathoracic organs (160 165)/(C30 39) 275 0.29 454 0.28 Lung and bronchus (162)/(C34) 265 0.29 443 0.29 Bone (170)/(C40-C41) 3 0.61 5 0.62 Skin (172 173)/(C43 44) 54 0.93 78 0.83 Melanoma (172)/(C43) 48 1.1 59 0.84 Other nonepithelial skin (173)/(C44) 6 0.42 19 0.81 Soft tissue (171)/(C45-C49) 23 0.91 36 0.87 Breast (174 175)/C50) 21 0.1 64 0.77 Genitourinary organs (179 189)/(C51-C68) 249 0.67 456 0.70 Prostate (185)/(C61) 148 0.69 304 0.80 Urinary bladder (188)/(C67) 42 0.67 53 0.49 Kidney and renal pelvis (189)/(C64-C65) 44 0.65 68 0.61 Brain and central nervous system (including benign) (191 59 0.78 130 1.06 192, 225)/(C70-C72, D32-D33, D35.2-D35.3, D42-D43) Brain and central nervous system (191 192)(C70-C72) 52 0.77 119 1.09 Thyroid (193)/(C73) 9 1.87 7 0.87 All lymphoid and hematopoetic (200.0 200.8, 201.0 201.9, 215 0.88 319 0.77 202.0 202.2, 202.8 202.9, 203.0 203.2, 204.0 204.2, 204.8 204.9, 208.0 208.2, 208.8 208.9)/(C81-C88, C90.0, C90.2, C91.0-C91.9, C95-C96) Total leukemia (204, 0, 204.1, 204.2, 204.8, 204.9, 205.0, 84 0.86 117 0.71 205.1, 206.0, 207.0, 207.2, 208.0, 208.1, 208.2, 208.8, 208.9; C91.0 91.4, C92.0,C92.1, C92.4, C92.5, C93.0, C94.0, C94.2, C95) Leukemia excluding chronic lymphocytic leukemia (204.0, 47 0.82 60 0.63 205.0 205.1, 206.0, 207.0, 207.2)/(C91.0, C92.0-C92.1, C92.4- C92.5, C93.0, C94.0, C94.2) Total lymphoma (200.0 200.8, 201.0 201.9, 202.0 202.2, 101 0.93 156 0.87 202.8)/(C C8182-C88); All myeloid (205.0, 205.3, 205.8 205.9, 206.0 206.2, 59 0.84 75 0.64 206.8 206.9, 207.0 207.2, 238.7, 285.0)/(C92.0-C92.5, C92.7, C92.9, C93.0-C93.2, C93.7, C93.9, C94.0-C94.5, D45-D47.3) Acute myeloid leukemia and myelodysplastic syndrome (MDS) (205.0, 206.0 206.2, 207.0, 207.2, 238.7, 285.0)/(C92.0, C92.4-C92.5, C93.0, C94.0, C94.2, D46)* 44 0.84 48 0.54 Page 1 of 5

Acute myeloid and monocytic leukemia (205.0, 206.0 33 0.79 38 0.54 206.2, 207.0, 207.2)/(C92.0, C92.4-C92.5, C93.0, C94.0, C94.2) MDS (238.7, 285.0)/(D46) 11 1.06 10 0.56 Myeloproliferative disorders (202.6, 205.1 205.2, 238.4 13 0.9 21 0.87 238.5)/(C92.1-C92.2, D45, D47.0-D47.1, D47.3) Chronic myeloid leukemia (205.1)/(C92.1) 10 0.97 16 0.93 Other myeloid leukemia (205.3, 205.8 205.9)/(C92.3, C92.7, C92.9, C94.1) 2 0.93 6 1.64 Other myeloid malignancies (206.8 206.9, 207.1)/(C93.1-0 0 0 0 C93.2, C93.7, C93.9, C94.2-C94.5) All lymphoid (200.0 200.8, 201.0 201.9, 202.0 202.2, 202.8 202.9, 203.0 203.2, 204.0 204.2, 204.8 204.9)/(C81- C88, C90.0, C90.2, C91.0-C91.9) 162 0.88 259 0.84 NHL (200.0 200.8, 202.0 202.2, 202.8 202.9)/(C82-C88) 95 0.94 151 0.9 Chronic lymphocytic leukemia (204.1, 204.2)/(C91.1-17 0.86 26 0.77 C91.3) Acute lyphocytic leukemia (204.0)/(C91.0) 4 0.80 6 0.75 Other lymphoid leukemia (204.8 204.9)/(C91.4-C91.9) 0 0 3 1.09 Multiple myeloma (203.0 203.2)/(C90.0, C90.2) 40 0.84 65 0.8 Hodgkin lymphoma (201.0 201.9)/(C81) 6 0.71 8 0.59 Other leukemias of unspecific cell type (208.0 208.2, 208.8 18 0.8 21 0.55 208.9)/(C95) Other and unspecific malignant neoplasms of lymphoid, 0 0 0 0 hematopoietic and related tissue (202.5, 202.8 202.9)/(C96) Infectious diseases (001 139)/(A00-B99) 91 0.32 294 0.68 Human immunodeficiency virus (042 044)/(B20-B24) 40 0.32 169 0.97 Septicemia (038)/(A40-A41) 15 0.17 49 0.32 Diseases of blood-forming tissue (280 289)/(D50-D89) 21 0.65 34 0.62 Aplastic anemia (284.8, 284.9)/(D61.3, D61.8, D61.9) 5 1.66 4 0.77 All endocrine disorders (240 279)/(E00-E90) 122 0.38 228 0.43 Disorders of the thyroid gland (240 246)/(E00-E90) 0 0 2 0.52 Diabetes mellitus (250)/(E10-E14) 93 0.37 158 0.38 All mental and behavioral disorders (290 319)/(F00-F99) 60 0.51 101 0.53 Neurologic and mental conditions (320 389)/(G00-G99) 185 0.91 312 0.9 Alzheimers (331.0)/(G30) 51 0.91 98 0.97 Other degenerative diseases of the nervous system (331.1 53 1.50 68 1.08 337.9)/(G31-G32) All circulatory diseases (390 459)/(I00-I99) 1653 0.45 3093 0.49 Hypertension without heart disease (401)/(I10) 7 0.29 22 0.54 Ischemic heart disease (410 414)/(I20-I25) 981 0.45 1848 0.50 Other diseases of heart (420 429)/(I30-I52) 250 0.39 513 0.46 Cerebrovascular diseases (430 438)/(I60-I69) 242 0.52 411 0.50 Atherosclerosis (440)/(I70) 15 0.40 35 0.51 Aortic aneurysm and dissection (441)/(I71) 44 0.53 88 0.61 All diseases of the respiratory system (460 519)/(J00-J99) 240 0.30 499 0.36 Pneumonia and influenza (480 487)/(J10-J18) 72 0.36 172 0.49 Chronic obstructive pulmonary disease and allied conditions 107 0.24 209 0.26 (490 496)/(J40-J47) All gastrointestinal diseases (520 579)/(K00-K93) 139 0.35 222 0.35 Chronic liver disease and cirrhosis (571)/(K70-K77) 62 0.29 80 0.24 All genitourinary diseases (580 629)/(N00-N99) 65 0.42 120 0.45 Nephritis, nephrotic syndrome/glomerular disease (580 589)/(N00-N08) 20 0.45 46 0.57 Page 2 of 5

Accidents and adverse effects (800 949)/(V01-X59, Y85-Y86) 316 0.49 660 0.67 Suicide and self-inflicted injury (E950-E959)/(U03, X60-X84, 170 0.88 394 1.38 Y87.0) Homicide and legal intervention (E960-E969)/(U01-U02, X85- Y09, Y87.1) 13 0.14 41 0.31 Note. Except where noted, data are for men and women combined. * Includes all malignant, benign, and uncertain behavior. Page 3 of 5

Table E2. RRs and 95% CIs for Deaths from All Causes, All Cancers, Site-specific Cancers, and Circulatory Diseases in All Exposed Radiologists Compared with Male Psychiatrists Who Were Confirmed Alive or Deceased: Sensitivity Analysis Causes of Death (ICD 9 <1940 1940 1959 1960 1979 1980+ P Value for Overall and 10 Codes) Trend Deaths* RR Deaths* RR Deaths* RR Deaths* RR Deaths* RR All causes of death 712/1415 0.94 (0.86, 1.03) 2427/4389 0.95 (0.91, 1.00) 973/1689 0.82 (0.76, 0.89) 148/322 0.63 (0.51, 0.76) <.001 4260/7815 0.91 (0.87, 0.94) All malignant neoplasms 190/321 1.10 (0.92, 1.32) 745/1330 0.96 (0.88, 1.05) 337/528 0.90 (0.79, 1.04) 34/57 0.86 (0.56, 1.34).37 1306/2236 0.96 (0.90, 1.03) (140 208, 238.6)/(C00-C97) Brain and central nervous 1/11 0.17 (0.02, 1.29) 26/59 0.75 (0.47, 1.20) 24/37 0.86 (0.52, 1.45) 6/12 0.67 (0.25, 1.79).33 57/119 0.73 (0.53, 1.01) system (including benign) (191 192, 225)/(C70-C72, D32-D33, D35.2-D35.3, D42-D43) Brain and central 1/9 0.20 (0.02, 1.58) 23/54 0.73 (0.45, 1.19) 22/34 0.85 (0.50, 1.46) 6/11 0.71 (0.26, 1.94).49 52/108 0.73 (0.52, 1.02) nervous system (191 192)(C70-C72) Total leukemia (204, 0, 204.1, 204.2, 204.8, 204.9, 205.0, 205.1, 206.0, 207.0, 207.2, 208.0, 208.1, 208.2, 208.8, 208.9; C91.0 91.4, C92.0,C92.1, C92.4, C92.5, C93.0, C94.0, C94.2, C95) 11/11 1.87 (0.82, 4.32) 44/59 1.28 (0.86, 1.90) 20/33 0.85 (0.49, 1.49) 2/2 1.19 (0.16, 9.03).45 77/105 1.19 (0.88, 1.60) Leukemia excluding CLL (204.0, 205.0 205.1, 5/3 3.21 (0.77, 13.45) 23/32 1.24 (0.72, 2.11) 14/16 1.20 (0.58, 2.45) 2/1 1.92 (0.17, 22.0) >.50 44/52 1.34 (0.90, 2.01) 206.0, 207.0, 207.2)/(C91.0, C92.0-C92.1, C92.4-C92.5, C93.0, C94.0, C94.2) Acute myeloid leukemia and myelodysplastic syndrome (MDS) (205.0, 206.0, 2, 207.0, 207.2, 238.7, 285.0)/(C92.0, C92.4- C92.5, C93.0, C94.0, C94.2, D46) b 4/2 3.66 (0.67, 20.02) 22/28 1.35 (0.77, 2.37) 11/9 1.69 (0.70, 4.09) 3/0 NA.24 40/39 1.64 (1.05, 2.56) All circulatory diseases (390 459)/(I00-I99) 364/756 0.90 (0.80, 1.02) 944/1719 0.95 (0.88, 1.03) 290/452 0.96 (0.83, 1.12) 22/52 0.62 (0.37, 1.03).34 1620/2979 0.94 (0.88, 1.00) Ischemic heart disease 211/456 0.86 (0.73, 1.02) 563/1044 0.94 (0.84, 1.04) 176/271 0.97 (0.80, 1.17) 12/27 0.67 (0.34, 1.33) >.50 962/1798 0.92 (0.85, 0.99) (410 414)/(I20-I25) Cerebrovascular diseases (430 438)/(I60- I69) 77/101 1.46 (1.08, 1.96) 133/219 1.06 (0.85, 1.31) 27/60 0.71 (0.45, 1.13) 2/6 0.43 (0.09, 2.16).04 239/386 1.09 (0.93, 1.28) Page 4 of 5

* Data are numbers of radiologists/numbers of psychiatrists. Stratified according to year of attained age (30 34, 35 39, 40 44, 45 49, 50 54, 55 59, 60 64, 65 69, 70 74, 75 79, 80+), year of birth (1894 1903, 1904 1913, 1914 1923, 1924 1933, 1934 1943, 1944 1953, 1954 1963, 1964 1973, 1974 1983), and year of medical school graduation (< 1940, 1940 59, 1960 79, 1980+). Numbers in parentheses are 95% CIs. NA = not applicable. Page 5 of 5